Analysts at Janney Montgomery Scott assumed coverage on shares of Uniqure (NASDAQ:QURE) in a research report issued to clients and investors on Wednesday, The Fly reports. The brokerage set a “buy” rating on the biotechnology company’s stock.
A number of other equities research analysts also recently weighed in on QURE. Zacks Investment Research downgraded Uniqure from a “hold” rating to a “sell” rating in a research note on Wednesday, October 18th. Leerink Swann raised their price target on Uniqure from $17.00 to $19.00 and gave the stock an “outperform” rating in a research note on Friday, October 20th. Evercore ISI started coverage on Uniqure in a research note on Tuesday, November 7th. They set an “outperform” rating and a $22.00 price target for the company. Oppenheimer reaffirmed a “hold” rating on shares of Uniqure in a research note on Friday, November 24th. Finally, HC Wainwright started coverage on Uniqure in a research note on Friday, December 1st. They set a “buy” rating and a $28.00 price target for the company. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $19.29.
Uniqure (QURE) traded down $0.34 on Wednesday, hitting $19.82. The stock had a trading volume of 537,165 shares, compared to its average volume of 443,633. Uniqure has a 52 week low of $4.72 and a 52 week high of $21.35. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.64 and a quick ratio of 3.64. The stock has a market cap of $610.46, a P/E ratio of -7.59 and a beta of 0.72.
Several hedge funds have recently modified their holdings of the stock. Mangrove Partners raised its stake in shares of Uniqure by 167.4% in the 3rd quarter. Mangrove Partners now owns 106,634 shares of the biotechnology company’s stock valued at $1,024,000 after acquiring an additional 66,763 shares in the last quarter. OxFORD Asset Management LLP bought a new position in shares of Uniqure in the 3rd quarter valued at approximately $399,000. FMR LLC raised its stake in shares of Uniqure by 4.1% in the 2nd quarter. FMR LLC now owns 1,560,113 shares of the biotechnology company’s stock valued at $9,656,000 after acquiring an additional 61,650 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Uniqure by 33.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 58,481 shares of the biotechnology company’s stock valued at $362,000 after acquiring an additional 14,659 shares in the last quarter. 24.87% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Uniqure (QURE) Earns Buy Rating from Analysts at Janney Montgomery Scott” was first published by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/03/uniqure-qure-earns-buy-rating-from-analysts-at-janney-montgomery-scott.html.
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.